NEW INDICATION REGISTERED FOR THE MEDICINE FORCIGA® (DAPAGLIFLOZIN): CHRONIC KIDNEY DISEASE
References
1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi: https://doi.org/10.1056/NEJMoa2024816
2. Инструкция по медицинскому применению лекарственного препарата Форсига® (таблетки, покрытые пленочной оболочкой, 5 мг,10 мг). Регистрационное удостоверение № ЛП 002596 от 21.08.2014
Review
For citations:
NEW INDICATION REGISTERED FOR THE MEDICINE FORCIGA® (DAPAGLIFLOZIN): CHRONIC KIDNEY DISEASE. Diabetes mellitus. 2021;24(5):487. (In Russ.)
Views:
26822
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
